Factors Influencing Achaogen (AKAO) Reaction; UBS Boosts View On Envestnet (ENV)


Achaogen, Inc. (Nasdaq:AKAO) stock climbed near 90% to touch the $6.06 mark in early trade Thursday after the clinical-stage biopharmaceutical company announced an approx. $25 million private placement from the sale of its common stock and warrants, and said that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its $20 million option to support continued development of Achaogen’s plazomicin

AKAO stock is trading at $3.63, up $0.44 (or +13.63%) and 8,355,915 of its shares changed hands so far, representing a large increase in activity versus its average volume (3m) of 86,956

Achaogen, which discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections, has 18.41M Shares Outstanding and AKAO stock 52-week range is from $2.59 to $7.74 per share



Envestnet, Inc. (NYSE:ENV) shares surged on Thursday’s trading session after investment analysts at UBS upgraded the company’s stock from Neutral to Buy and significantly boosted their price target from $33.00 to $44.00

The wealth management technology provider recently delivered first quarter 2016 adjusted revenues of $132.0 million, representing a 37% increase year over year.

ENV stock is changing hands at $35.95, up $1.99 (or +5.86%) with 759,322 shares traded so far

Envestnet, which provides technology-enabled, Web-based investment solutions and services to financial advisors, has 42.69M Shares Outstanding and ENV stock one-year range is between $19.30 and $46.45 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/